Understanding age influences vaccine response is key for effective SARS-CoV-2 vaccine design.
In a study of 312 people vaccinated with the BNT162b2 vaccine, most showed strong antibody and T cell responses, although antibody effectiveness decreased against Delta and Omicron variants.
Older adults (≥60 years) had lower antibody responses but developed longer-lasting immunity over six months, and a third vaccine dose significantly improved their antibody responses against all variants.